Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug symbols : Pfe save search
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: -1.77%
TNXP | $0.1449 -10.83% -12.15% 5M
|
Health Technology
|
| O: 4.32%
H: 7.17%
C: 2.5%
drug fibromyalgia study
Global Sustained Release Coatings Markets, 2018-2022 and 2023-2028: Growing Demand for Controlled Drug Delivery Boosts Expansion
Published: 2024-02-01 (Crawled : 17:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -1.29%
H: 0.0%
C: -1.38%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.7%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.55%
H: 0.79%
C: 0.25%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 1.27%
H: 1.87%
C: 1.73%
EMN | $97.32 -0.67% 0.0% 1.4M
|
Process Industries
|
| O: 0.79%
H: 0.8%
C: 0.77%
drug expansion global growing
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.56%
H: 1.25%
C: -0.33%
keytruda drug japan bladder cancer treatment application advanced
Global CAR T-Cell Therapy Market Analysis Report 2023: Drug type, Indication, Target Antigen, End-user and Region - Forecast to 2030
Published: 2024-01-24 (Crawled : 17:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.39%
H: 0.82%
C: -0.74%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.22%
H: 0.43%
C: -0.39%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: 0.1%
H: 0.43%
C: -0.04%
AUTL | $4.9 -2.39% -2.45% 790K
|
Health Technology
|
| O: -0.91%
H: 11.52%
C: 4.94%
drug report t-cell global therapy market
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
GNMSF | $291.12 3.83% 300
|
Health Technology
|
| O: -3.69%
H: 1.71%
C: -2.41%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.07%
H: 0.88%
C: -0.68%
GMAB | $29.51 0.85% 0.85% 500K
|
Health Technology
|
| O: -1.1%
H: 0.46%
C: -0.06%
tivdak drug license review food cancer application
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
nefecon nephropathy drug approval treatment application
Global Nasal Drug Delivery Technology Market Projected to Reach $111.9 Billion by 2030
Published: 2023-08-23 (Crawled : 22:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 1.41%
H: 1.07%
C: -1.39%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -3.15%
H: 0.77%
C: 0.77%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -0.5%
H: 0.45%
C: -0.86%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.31%
H: 0.6%
C: -1.06%
ATR | $138.2 0.73% 0.0% 320K
|
Process Industries
|
| O: 0.08%
H: 1.6%
C: 1.31%
MMM | $91.3 -0.01% 0.31% 3.5M
|
Producer Manufacturing
|
| O: -0.38%
H: 1.41%
C: -0.78%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.39%
H: 0.46%
C: -1.37%
drug reach global technology market
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
Published: 2023-04-04 (Crawled : 11:00) - biospace.com/
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -1.3%
fda drug
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Published: 2023-02-10 (Crawled : 23:00) - biospace.com/
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.37%
H: 1.1%
C: 0.87%
cibinqo fda drug application
Everest Medicines' Licensing Partner Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis Everest Medicines announced that its licensing partner, Pfizer Inc. has received acceptance from the U.S. Food and Drug Administration for review a New Drug Application for etrasimod for individuals living with moderately-to-severely active ulcerative colitis.
Published: 2022-12-22 (Crawled : 07:00) - biospace.com/
CYDY | $0.157 0.06% 970K
|
Manufacturing
|
| O: -4.34%
H: 0.35%
C: -5.13%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -0.48%
H: 0.56%
C: 0.45%
fda drug active ema application review food living ulcerative colitis
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases
Published: 2022-12-01 (Crawled : 13:20) - globenewswire.com
ROIV | $10.85 -0.82% -0.83% 4.7M
|
Manufacturing
|
| O: 7.28%
H: 2.96%
C: 0.87%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.36%
H: 1.68%
C: 1.53%
drug candidate
Global Opioid Induced Constipation Drugs Market Report to 2030 - by Drug Type, Prescription Type and Region
Published: 2022-09-28 (Crawled : 15:00) - prnewswire.com
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: 2.35%
H: 0.0%
C: -0.68%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 1.32%
H: 0.31%
C: -0.54%
IRWD | $7.795 -1.08% -1.09% 2.5M
|
Health Technology
|
| O: 1.07%
H: 3.08%
C: 2.41%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: 0.04%
H: 3.14%
C: 2.68%
drug global opioid report market
A $41.8 Billion Global Opportunity for Small Molecule Drug Discovery by 2026 - New Research from StrategyR
Published: 2022-07-04 (Crawled : 11:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
| Email alert
Add to watchlist
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | $20.07 -14.18% 1K
|
Health Technology
| Email alert
Add to watchlist
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.88 -4.19% 960
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
| Email alert
Add to watchlist
drug research
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
Published: 2022-06-30 (Crawled : 11:00) - biospace.com/
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 1.79%
H: 2.31%
C: 1.43%
fda drug application submission
Antihypertensive Drugs Market is Estimated to Rise at a CAGR of 3% during the Forecast Period, observes TMR Study
Published: 2022-06-15 (Crawled : 12:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -1.02%
H: 1.6%
C: 1.14%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
market drug
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Published: 2022-06-02 (Crawled : 11:00) - globenewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -1.62%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -2.98%
H: 0.0%
C: 0.0%
myfembree fda sciences drug application
Antifungal Drugs Market Size to be worth $20.5 Billion by 2030: Grand View Research, Inc.
Published: 2022-05-24 (Crawled : 12:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -2.41%
H: 0.0%
C: -1.7%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
ENZN | $0.0948 136.11% 1.1K
|
Manufacturing
|
| O: -4.13%
H: 4.38%
C: 1.01%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.04%
H: 1.53%
C: 1.37%
market drug
Hydrogel-Based Drug Delivery System Market to Surpass US$ 8,187.6 Million by 2030 - Coherent Market Insights
Published: 2022-05-18 (Crawled : 18:00) - prnewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -0.23%
H: 0.39%
C: -1.6%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: 0.0%
drug system market
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Published: 2022-05-06 (Crawled : 11:00) - globenewswire.com
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: -2.36%
H: 0.0%
C: 0.0%
MYOV | $26.98 -0.04% 0.0% 0
|
Health Technology
|
| O: -1.71%
H: 0.0%
C: 0.0%
myfembree management drug application
Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth
Published: 2022-04-26 (Crawled : 14:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: 2.56%
H: 0.0%
C: 0.0%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.13%
H: 0.06%
C: -0.69%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.47%
H: 0.83%
C: -1.44%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 2.0%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.34%
H: 1.41%
C: -1.17%
IONS | $41.56 -0.43% -0.43% 760K
|
Health Technology
|
| O: -0.12%
H: 0.07%
C: -5.13%
research report growth market drug
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.